Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Novo Nordisk Increases Dosage in Weight Loss Drug Test, Showing Improvement but Still Behind Eli Lilly's Rival Drug
Recommend 3 Positive 7 Negative 3 |
||||
|
||||
|
Danish pharma company Novo Nordisk A/S (NVO.US) increased the dosage of its obesity treatment drug by 3x in a clinical trial, resulting in better weight loss outcomes for patients, according to the Financial Times. The Company's semaglutide was tested at a dosage of 7.2 mg in two late-stage clinical trials, which is three times the currently approved maximum dose of 2.4 mg. Results show that patients lost an average of 19% of their body weight after 72 weeks, still trailing behind Eli Lilly and Company (LLY.US)'s tirzepatide, which reported an average weight loss of 22.5%. However, experts suggested that, if competitively priced, the 7.2 mg semaglutide could represent a more affordable alternative. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
